Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of Galcanezumab in Cluster Headache
NCT02797951Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Jul 2016
- Primary completion
- Jan 2021
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 12
01
Overview
Phase 3, open-label, single-arm trial of galcanezumab in Cluster Headache (CH), sponsored by Eli Lilly and Company. Primary endpoints: Number of Participants With Treatment Emergent Adverse Events (TEAEs) and Serious AEs (SAEs) up to 4 Years and Number of Participants With Suicidal Ideation and Behaviours Collected by Columbia - Suicide Severity Rating Scale (C-SSRS) up to 4 Years. Started Jul 2016; status: completed.
02
Drugs
galcanezumab
03
Conditions
Cluster Headache (CH)
Beyond the preview
Go deeper on NCT02797951.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02797951.